Straits Times Index
3,405.81 -5.00 (-0.15%) Nikkei
40,780.70 -131.67 (-0.32%) Hang Seng
17,524.06 -275.55 (-1.55%) FTSE 100
8,219.87 +15.94 (+0.19%) Bitcoin USD
57,168.60 -307.71 (-0.54%) CMC Crypto 200
1,178.35 +12.23 (+1.05%)
ARDX Jan 2025 1.500 call
| Previous close | 4.1000 |
| Open | 4.1000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 1.50 |
| Expiry date | 2025-01-17 |
| Day's range | 4.1000 - 4.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireTo Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
Ardelyx continues support for bipartisan legislation that would extend the exclusion of oral-only medications from entering the CMS Prospective Payment System Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that, in an effort to pr
- GlobeNewswire
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data detailing educational needs related to irritable bowel syndrome with constipation (IBS-C) across healthcare disciplines was presented via a poster at the 2024 American Association of Nurse Practitioners (AANP) Annual Confere
Simply Wall St.When Will Ardelyx, Inc. (NASDAQ:ARDX) Become Profitable?
With the business potentially at an important milestone, we thought we'd take a closer look at Ardelyx, Inc.'s...
